2024
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare
2015
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer
Bitterman DS, Salgado L, Moore HG, Sanfilippo NJ, Gu P, Hatzaras I, Du KL. Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer. Frontiers In Oncology 2015, 5: 286. PMID: 26734570, PMCID: PMC4686647, DOI: 10.3389/fonc.2015.00286.Peer-Reviewed Original ResearchDistant metastasis-free survivalDisease-free survivalComplete responseLocoregional controlCarcinoembryonic antigenAnal vergeIndependent predictorsRectal cancerTumor sizeCR groupNode-positive rectal cancerThree-year locoregional controlNode-positive diseaseDistance of tumorNon-operative managementMetastasis-free survivalLong-term outcomesTreatment response evaluationDefinitive chemoradiationRectal patientsNeoadjuvant chemoradiationMost patientsNode positivityOverall survivalSelect patientsHIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era
Grew D, Bitterman D, Leichman CG, Leichman L, Sanfilippo N, Moore HG, Du K. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. Diseases Of The Colon & Rectum 2015, 58: 1130-1136. PMID: 26544809, DOI: 10.1097/dcr.0000000000000476.Peer-Reviewed Original ResearchConceptsHIV-negative patientsHIV-positive patientsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraColostomy-free survivalOverall survival rateAnal cancerSurvival rateTherapy eraMultivariate analysisColostomy-free survival ratesLocal recurrence-free survivalDistant metastasis-free survivalRetrospective chart reviewSmall patient numbersRecurrence-free survivalMetastasis-free survivalOutpatient oncology clinicsLarge academic centerDefinitive chemoradiationDefinitive chemoradiotherapyChart reviewOverall survivalPatient characteristicsHIV infectionComparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center
Bitterman DS, Grew D, Gu P, Cohen RF, Sanfilippo NJ, Leichman CG, Leichman LP, Moore HG, Gold HT, Du KL. Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center. Journal Of Gastrointestinal Oncology 2015, 6: 524-33. PMID: 26487947, PMCID: PMC4570920, DOI: 10.3978/j.issn.2078-6891.2015.061.Peer-Reviewed Original ResearchDisease-free survivalColostomy-free survivalOverall survivalPublic hospital patientsPrivate hospital patientsHospital patientsRadiotherapy durationFree survivalRadiotherapy delayRadiation therapyHigher clinical T stageThree-year overall survivalPoor disease-free survivalPrivate hospitalsAdvanced anal cancerAnal cancer outcomesSame cancer centerUnplanned treatment breaksClinical T stageAnal cancer patientsKaplan-Meier methodLow socioeconomic status populationClinical stage groupsLog-rank testProportional hazards modelRadiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data
Modrek AS, Hsu HC, Leichman CG, Du KL. Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data. Radiation Oncology 2015, 10: 101. PMID: 25902707, PMCID: PMC4464878, DOI: 10.1186/s13014-015-0411-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyDigestive System Surgical ProceduresFemaleHumansKaplan-Meier EstimateMaleMiddle AgedOrganoplatinum CompoundsProportional Hazards ModelsRectal NeoplasmsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesConceptsRadiation therapyOverall survivalRectal cancerSurveillance EpidemiologyCell carcinomaSEER dataMultivariate Cox proportional hazards modelCox proportional hazards modelBackgroundSmall cell carcinomaMethodsThe SEER databaseCancer-directed therapyEnd Results (SEER) databaseUnadjusted hazard ratioEnd Results (SEER) dataKaplan-Meier methodOverall survival rateYear of diagnosisSmall cell carcinomaSignificant survival advantagePearson's chi-square testProportional hazards modelOnly significant factorChi-square testChemotherapy usageLocoregional casesAnal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy.
Cooper B, Grew D, Bitterman D, Sanfilippo N, Du K. Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy. Journal Of Clinical Oncology 2015, 33: 662-662. DOI: 10.1200/jco.2015.33.3_suppl.662.Peer-Reviewed Original ResearchDistant metastasis-free survivalLocal recurrence-free survivalColostomy-free survivalOverall survivalTreatment interruptionLymph nodesTreatment breaksSkin toxicityRadiation therapyThree-year overall survivalAnal cancer outcomesGrowth factor supportRecurrence-free survivalMetastasis-free survivalSquamous cell carcinomaKaplan-Meier survivalConformal radiation therapyRadiation techniquesLog-rank statisticsChi-square testAcute gastrointestinalAcute GIDefinitive chemoradiotherapyIMRT cohortRTOG 0529
2014
Outcomes of rectal cancer with liver oligometastases
Resende Salgado L, Hsu H, Du K. Outcomes of rectal cancer with liver oligometastases. Journal Of Gastrointestinal Oncology 2014, 5: 414-20. PMID: 25436119, PMCID: PMC4226821, DOI: 10.3978/j.issn.2078-6891.2014.078.Peer-Reviewed Original ResearchRectal cancer patientsTotal mesorectal excisionProgression-free survivalCourse chemoradiationLiver metastasesOverall survivalCancer patientsLocal controlRectal cancerDistant metastasisMean PFS timeOligometastatic colorectal cancerOligometastatic rectal cancerPelvic lymph nodesKaplan-Meier methodMulti-modality treatment approachSingle institution experienceTime of diagnosisGoals of careKaplan-Meier analysisEquivalent local controlMean survival timeLong-term survivalYears of ageCensoring deathsChemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology 2014, 86: 79-85. PMID: 24435019, DOI: 10.1159/000354641.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdjuvant chemoradiationSurgical resectionOverall survivalRandomized trialsGastric cancerMantel-Haenszel random-effects modelHigher disease-free survivalCategory 1 recommendationNew systemic agentsR0 surgical resectionCurrent national guidelinesSignificant differencesRandom-effects modelAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimenChemoradiation therapySystemic agentsPrimary outcomeGastric adenocarcinomaClinical trialsChemoradiationNational guidelinesResection
2011
Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials
Du KL, Bae K, Movsas B, Yan Y, Bryan C, Bruner DW. Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials. Supportive Care In Cancer 2011, 20: 1317-1325. PMID: 21720747, DOI: 10.1007/s00520-011-1219-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsMaleMarital StatusMiddle AgedPrognosisProportional Hazards ModelsProstatic NeoplasmsRacial GroupsRandomized Controlled Trials as TopicSurvival RateTime FactorsTreatment FailureTreatment OutcomeConceptsPathologic prognostic factorsPrognostic factorsProportional hazards modelOverall survivalMedian timeSociodemographic factorsWhite patientsCancer outcomesPrognostic indicatorProstate cancerMarital statusImproved prostate cancer outcomesHigh-risk cancer patientsGray proportional hazards modelsCommon visceral cancerOutcomes of patientsBiochemical failure rateCumulative incidence methodSignificant prognostic factorsCancer-related outcomesKaplan-Meier methodProstate cancer outcomesGroup of patientsNon-white patientsProstate cancer risk
2007
Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome. International Journal Of Radiation Oncology • Biology • Physics 2007, 69: 1024-1031. PMID: 17967299, PMCID: PMC2737259, DOI: 10.1016/j.ijrobp.2007.04.067.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaPatient outcomesNeck squamous cell tumorsNeck squamous cell carcinomaEvent-free survival timeShorter event-free survival timePositron emission tomographic studiesSquamous cell tumorsLevels of hypoxiaEmission tomographic studiesNodal statusOverall survivalTreatment regimenPrognostic significanceCell tumorsPrimary headMajority of cellsSurvival timeOral cavityHypoxia markersQuantitative immunohistochemistryEF5 bindingSevere hypoxiaPatients